Name Address/P.O. Box Postal Code/City Country Contact Person Telephone Fax Email Website Social Media Number of Employees Founded (year) Type of Laboratory
Areas of Activity
External
›
Ex-Big Pharma drug hunters
IRBM S.p.A
›
Via Pontina Km 30,600 00071 Pomezia (Rome) Italy Heidi Kingdon Jones +39-06-91093-692 +39-06-91093-654 bd@irbm.com / h.kingdon@irbm.com https://www.irbm.com/
›
I
› › › › › › ›
› › ›
›
›
Collaborations
Member of
200 2009 | Chemistry | Biology | NMR | Animal facility | Analytics | Prep lab (Kg-scale, non GMP) | BSL 1, 2, 2+ Integrated drug discovery | Display technologies | Antibody discovery | Peptide drug discovery | Small molecule drug discovery | Biomarker identification and development | Discovery and translational biology | High-content and high-throughput biology and screening | ADME/DMPK | In vivo pharmacology | Structural biology and virtual screening | Antios Therapeutics | MSD | MD Anderson Cancer Center | AstraZeneca (with IRBM’s Advent) | CHDI
European Biotechnology Net work
IRBM is a former MSD site operating as an innovative contract research organisation working across all aspects of drug discovery and early development for different modalities – small molecules, peptides and antibodies.
Excellent drug discovery track record Scientific excellence is in our DNA. Our team has invented and worked on 4 marketed drugs: ISENTRESS® (a first-in-class HIV integrase inhibitor), ZOLINZA® (the first HDAC inhibitor for non-small cell lung cancer), Grazoprevir (ZEPATIER® for HCV), and ZEJULA® (a PARP inhibitor for ovarian cancer). We have delivered over 25 preclinical candidates, and published an unprecedented number of papers.
Customised solutions for each project Based on our experience, IRBM offers tailored solutions to clients and contributes know-how as well as critical assessment of the results. As many of the studies are exploratory by nature, IRBM often uses its strong scientific foundation to develop completely novel methods and experimental set-ups. Through our scientific expertise, providing insights and the highest quality standards, we advance your project swiftly and cost-effectively without compromising on quality.
Target to candidate nomination We foster collaborations with organisations from the pharmaceutical, biotech, and academic sectors to accelerate drug discovery from target validation and hit identification to candidate nomination. Our 200-plus strong, multidisciplinary team works at a state-of-theart R&D facility near Rome where projects are carried out “under one roof” enabling rapid cycle times and close integration of the scientific teams.
